Cargando…
IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963768/ https://www.ncbi.nlm.nih.gov/pubmed/35368385 http://dx.doi.org/10.1016/S2665-9913(22)00090-X |
| _version_ | 1784678060758401024 |
|---|---|
| author | Bassiri, Hamid Canna, Scott W |
| author_facet | Bassiri, Hamid Canna, Scott W |
| author_sort | Bassiri, Hamid |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8963768 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89637682022-03-30 IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 Bassiri, Hamid Canna, Scott W Lancet Rheumatol Comment Elsevier Ltd. 2022-05 2022-03-29 /pmc/articles/PMC8963768/ /pubmed/35368385 http://dx.doi.org/10.1016/S2665-9913(22)00090-X Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Bassiri, Hamid Canna, Scott W IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title | IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title_full | IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title_fullStr | IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title_full_unstemmed | IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title_short | IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 |
| title_sort | il-1 receptor antagonist, mis-c, and the peculiar autoimmunity of sars-cov-2 |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963768/ https://www.ncbi.nlm.nih.gov/pubmed/35368385 http://dx.doi.org/10.1016/S2665-9913(22)00090-X |
| work_keys_str_mv | AT bassirihamid il1receptorantagonistmiscandthepeculiarautoimmunityofsarscov2 AT cannascottw il1receptorantagonistmiscandthepeculiarautoimmunityofsarscov2 |